NCT04753229 (TNE-P-Ki) is a clinical trial in Neuroendocrine Tumors, sponsored by Institut Paoli-Calmettes.

Who is sponsoring NCT04753229?

NCT04753229 is sponsored by Institut Paoli-Calmettes.

What condition does NCT04753229 study?

NCT04753229 studies Neuroendocrine Tumors.

Is NCT04753229 still recruiting?

NCT04753229 is currently completed. Last updated 18 February 2021.

Last reviewed 2021-02-18 · How we verify

NCT04753229: TNE-P-Ki

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia

Completed Last updated 18 February 2021

What this trial tests

trial in Neuroendocrine Tumors in 50 participants. Completed in 1 October 2020.

Timeline

1 January 2008

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 January 2008
Primary completion	1 October 2020
Estimated completion	1 October 2020

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective, monocentric study involving 50 patients with pancreatic neuroendocrine neoplasia resected between January 2008 and June 2020 at Paoli Calmettes Institute. The primary objective of the study is to evaluate the grade concordance rate, based on Ki67 obtained on the pre-operative micro-biopsy and the surgical specimen. Based on the histology slides obtained in the course of the treatment, several Ki67 recounts will be performed on pre-operative tumor micro-biopsies and on tumors resected after surgery: * a manual count (on photo printed in the hotspot area according to World Health Organization (WHO) 2017 recommendations, by an expert pathologist and a junior pathologist. * Automated counting using specific software based on artificial intelligence (Qpath software). On the other hand, clinical, surgical and anatomopathological data will be collected in order to follow the patient evolution.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04753229 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 18 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04753229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing